AnaCardio Raises €62.5M in Series B Funding

AnaCardio, a Swedish clinical-stage biopharmaceutical company, has raised €62.5 million in a Series B funding round.

The company confirmed the financing, which ranks among the larger European biotech raises reported this year by deal trackers.

AnaCardio develops drugs for heart failure, an area where treatment innovation has lagged despite the disease's heavy toll on health systems. The Series B proceeds are intended to fund the company's clinical programs.

The round signals continued investor appetite for cardiovascular drug development, a field that has drawn renewed venture attention after years of preference for oncology and rare diseases.

Heart failure affects tens of millions of patients worldwide, and the market for new therapies remains substantial. AnaCardio's ability to close a €62.5 million round suggests backers see credible clinical promise in its pipeline.

The funding will support the company as it works to move its candidates through clinical development, a capital-intensive process where Series B capital typically carries trials into later-stage testing.

For AnaCardio, the next milestones will be clinical readouts that determine whether the investment translates into a viable therapeutic candidate.